Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BOLD 100

Drug Profile

BOLD 100

Alternative Names: BOLD 100; IT-139; KP 1339; NKP-1339

Latest Information Update: 07 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medical University of Vienna; Queens University Belfast; University of Vienna
  • Developer Bold Therapeutics; Georgetown University; Hana Pharm; Intezyne; University of Ottawa
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; DNA inhibitors; Molecular chaperone GRP78 protein inhibitors; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer; Pancreatic cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Biliary cancer; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Pancreatic cancer
  • Preclinical COVID 2019 infections; Triple negative breast cancer
  • No development reported Solid tumours

Most Recent Events

  • 03 Jun 2024 Efficacy and adverse events data from a phase Ib/IIa trial in Biliary cancer and Gastric cancer released by Bold Therapeutics
  • 03 Jun 2024 Bold Therapeutics plans a phase II randomised trial for Colorectal cancer (Second-line therapy or greater, Combination therapy) in multiple countries (IV)
  • 05 Apr 2024 Pharmacodynamics data from the preclinical trial in Adenocarcinoma released by Bold Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top